GC–MS analysis of 4-hydroxyproline: elevated proline hydroxylation in metformin-associated lactic acidosis and metformin-treated Becker muscular dystrophy patients
Abstract Metformin (N,N-dimethylbiguanide), an inhibitor of gluconeogenesis and insulin sensitizer, is widely used for the treatment of type 2 diabetes. In some patients with renal insufficiency, metformin can accumulate and cause lactic acidosis, known as metformin-associated lactic acidosis (MALA, defined as lactate ≥ 5 mM, pH < 7.35, and metformin concentration > 38.7 µM). Here, we report on the post-translational modification (PTM) of proline (Pro) to 4-hydroxyproline (OH-Pro) in metformin-associated lactic acidosis and in metformin-treated patients with Becker muscular dystrophy (BMD). Pro and OH-Pro were measured simultaneously by gas chromatography–mass spectrometry before, during, and after renal replacement therapy in a patient admitted to the intensive care unit (ICU) because of MALA. At admission to the ICU, plasma metformin concentration was 175 µM, with a corresponding lactate concentration of 20 mM and a blood pH of 7.1. Throughout ICU admission, the Pro concentration was lower compared to healthy controls. Renal excretion of OH-Pro was initially high and decreased over time. Moreover, during the first 12 h of ICU admission, OH-Pro seems to be renally secreted while thereafter, it was reabsorbed. Our results suggest that MALA is associated with hyper-hydroxyprolinuria due to elevated PTM of Pro to OH-Pro by prolyl-hydroxylase and/or inhibition of OH-Pro metabolism in the kidneys. In BMD patients, metformin, at the therapeutic dose of 3 × 500 mg per day for 6 weeks, increased the urinary excretion of OH-Pro suggesting elevation of Pro hydroxylation to OH-Pro. Our study suggests that metformin induces specifically the expression/activity of prolyl-hydroxylase in metformin intoxication and BMD..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Amino acids - 56(2024), 1 vom: 10. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baskal, Svetlana [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
4-Hydroxyproline |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1007/s00726-024-03383-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055090966 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055090966 | ||
| 003 | DE-627 | ||
| 005 | 20240311095255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00726-024-03383-9 |2 doi | |
| 035 | |a (DE-627)SPR055090966 | ||
| 035 | |a (SPR)s00726-024-03383-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.76 |2 bkl | ||
| 100 | 1 | |a Baskal, Svetlana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a GC–MS analysis of 4-hydroxyproline: elevated proline hydroxylation in metformin-associated lactic acidosis and metformin-treated Becker muscular dystrophy patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Metformin (N,N-dimethylbiguanide), an inhibitor of gluconeogenesis and insulin sensitizer, is widely used for the treatment of type 2 diabetes. In some patients with renal insufficiency, metformin can accumulate and cause lactic acidosis, known as metformin-associated lactic acidosis (MALA, defined as lactate ≥ 5 mM, pH < 7.35, and metformin concentration > 38.7 µM). Here, we report on the post-translational modification (PTM) of proline (Pro) to 4-hydroxyproline (OH-Pro) in metformin-associated lactic acidosis and in metformin-treated patients with Becker muscular dystrophy (BMD). Pro and OH-Pro were measured simultaneously by gas chromatography–mass spectrometry before, during, and after renal replacement therapy in a patient admitted to the intensive care unit (ICU) because of MALA. At admission to the ICU, plasma metformin concentration was 175 µM, with a corresponding lactate concentration of 20 mM and a blood pH of 7.1. Throughout ICU admission, the Pro concentration was lower compared to healthy controls. Renal excretion of OH-Pro was initially high and decreased over time. Moreover, during the first 12 h of ICU admission, OH-Pro seems to be renally secreted while thereafter, it was reabsorbed. Our results suggest that MALA is associated with hyper-hydroxyprolinuria due to elevated PTM of Pro to OH-Pro by prolyl-hydroxylase and/or inhibition of OH-Pro metabolism in the kidneys. In BMD patients, metformin, at the therapeutic dose of 3 × 500 mg per day for 6 weeks, increased the urinary excretion of OH-Pro suggesting elevation of Pro hydroxylation to OH-Pro. Our study suggests that metformin induces specifically the expression/activity of prolyl-hydroxylase in metformin intoxication and BMD. | ||
| 650 | 4 | |a Amino acids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a BMD |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dialysis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GC–MS |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a 4-Hydroxyproline |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intoxication |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Kidney injury |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a MALA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mass spectrometry |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PTM |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Renal replacement therapy (RTR) |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Posma, Rene A. |4 aut | |
| 700 | 1 | |a Bollenbach, Alexander |4 aut | |
| 700 | 1 | |a Dieperink, Willem |4 aut | |
| 700 | 1 | |a Bakker, Stephan J. L. |4 aut | |
| 700 | 1 | |a Nijsten, Maarten W. |4 aut | |
| 700 | 1 | |a Touw, Daan J. |4 aut | |
| 700 | 1 | |a Tsikas, Dimitrios |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Amino acids |d Springer Vienna, 1991 |g 56(2024), 1 vom: 10. März |w (DE-627)SPR007611269 |w (DE-600)1480643-5 |x 1438-2199 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2024 |g number:1 |g day:10 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00726-024-03383-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.76 |q VZ |
| 951 | |a AR | ||
| 952 | |d 56 |j 2024 |e 1 |b 10 |c 03 | ||